Skip to main content

Table 2 American College of Rheumatology Core Components and Acute Phase Reactants

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

ACR Core Reactant

Components and Acute Phase

Baseline

Week 4

Week 8

Week 12

ACR Core Set

Tender joint count (0-68 scale)

14.9 ± 7.1

9.4 ± 7.1*

7.8 ± 7.1*

6.8 ± 6.8*

 

Swollen joint count (0-66 scale)

13.2 ± 5.2

8.7 ± 5.6*

7.4 ± 5.5*

6.4 ± 5.2*

 

Patient's assessment of pain, mm (0-100 mm VAS)a

66.2 ± 22.3

45.0 ± 26.4*

40.3 ± 26.9*

37.3 ± 27.5*

 

Patient's global assessment of disease activity, mm (0-100 mm VAS)b

65.1 ± 22.7

45.1 ± 25.7*

41.0 ± 26.7*

37.4 ± 27.2*

 

Physician's global assessment of disease activity, mm (0-100 mm VAS)b

63.6 ± 17.6

40.7 ± 22.5*

33.5 ± 22.4*

29.0 ± 22.7*

 

HAQ-DI score (0-3 scale)c

1.5 ± 0.6

1.2 ± 0.7*

1.1 ± 0.7*

1.0 ± 0.7*

Acute Phase Reactant

ESR (mm/h) normal value < 20 mm/h

30.3 ± 23.8

20.6 ± 20.1*

20.7 ± 19.7*

20.0 ± 18.6*

  1. *P < 0.001 vs. baseline.
  2. a0 = no pain and 100 = severe pain.
  3. b0 = no disease activity and 100 = extreme disease activity.
  4. c0 = no difficulty and 3 = unable to perform activity.
  5. ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; VAS: visual analog scale.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us